Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAV-muscle is a preclinical gene therapy program being developed by Latus Bio, focusing on the treatment of genetic muscle disorders. The program utilizes Latus Bio's proprietary adeno-associated virus (AAV) capsid engineering platform to create vectors with enhanced tropism for skeletal and cardiac muscle tissues. By improving the specificity and potency of delivery, the AAV-muscle candidates aim to achieve therapeutic gene expression at lower systemic doses compared to conventional AAV serotypes like AAV9, potentially reducing the risk of liver toxicity and other dose-dependent adverse effects. The specific genetic targets and indications within the muscle disorder space have not yet been publicly disclosed, but the program leverages the company's broader expertise in refining AAV delivery to transform treatment for genetic diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AAV-muscle.